NRX Pharmaceuticals, Inc. 8-K

What Happened NRX Pharmaceuticals, Inc. (NRXP) filed a prospectus supplement on February 17, 2026, for an aggregate of $20,000,000 of its common stock to be issued under its At-The-Market (ATM) Offering Agreement with H.C. Wainwright & Co., LLC. The shares would be issued under the company’s Form S-3 registration statement (File No. 333-288205), which was initially filed June 20, 2025 and declared effective December 22, 2025. The 8-K also includes a legal opinion from Cozen O’Connor regarding the validity of the shares (filed as Exhibit 5.1).

Key Details

• Aggregate amount: $20,000,000 of common stock available under the ATM prospectus supplement.
• Placement agent: H.C. Wainwright & Co., LLC; original Offering Agreement dated August 14, 2023 (as amended).
• Registration: Shares to be issued under Form S-3 (File No. 333-288205), declared effective Dec 22, 2025.
• Legal documentation: Opinion of Cozen O’Connor on share validity filed as Exhibit 5.1 (consent included).

Why It Matters This filing gives NRX a formal mechanism to raise up to $20 million by selling common shares into the market over time. If the company sells shares under the ATM, it would increase the number of shares outstanding (potentially dilutive) while providing capital flexibility. Investors should monitor subsequent SEC filings and company announcements for actual issuance amounts, timing, and any disclosed use of proceeds.